MANSFIELD, Mass. and
KANSAS CITY, Mo., June 3, 2020 /PRNewswire/ -- Transplant Genomics,
Inc. ("TGI") and Viracor Eurofins ("Viracor"), announce the
formation of the Eurofins Transplant Medical and Scientific
Advisory Board, employing diverse expertise and experience in
transplantation technology development and clinical studies to
enhance the clinical value of diagnostics throughout the transplant
community. The members will be tasked with providing independent
advice on the unmet clinical needs in transplantation to guide the
evolution of TGI and Viracor's current and future products
that expand the indications for the TruGraf and TRAC product lines
through Clinical Studies, and the R&D or acquisition of
additional disruptive technologies into the Eurofins Transplant
portfolio. The Board will be convened by Dr. John Holman, VP Medical Affairs at Eurofins -
TGI.
Covering the breadth of geographies within the US market, the
Board welcomes Dr. Roz Mannon, University of Nebraska;
Dr. Michael Abecassis, University of Arizona; Dr. Fuad Shihab, University of
Utah; Dr. Win Williams, Massachusetts General Hospital; Dr. Anil
Chandraker, Brigham and Women's Hospital; Dr. Allan Kirk, Duke
University (joining in August after completing his term as
Editor-in-Chief of AJT); Dr. Jonathan
Bromberg, University of
Maryland, Dr. Robert
Fairchild, Cleveland Clinic, and Dr. Matt Cooper, Georgetown
University.
Advisor Dr. Johnathan Bromberg,
Professor of Surgery and Microbiology and Immunology at the
University of Maryland says, "For
too long transplant patients have had limited or invasive
diagnostic options, so it is tremendously exciting to join a Board
with a mission in science and medicine to improve current
diagnostic options available to transplant patients, and
subsequently offer physicians better tools to alter and improve our
approach to treatment."
Advisor Dr. Michael Abecassis,
Dean of the University of Arizona,
College of Medicine - Tucson,
says, "The formation of this Board will help to expand the
product portfolio to create new opportunities for the powerful
commercial teams assembled by TGI and Viracor." By combining
TruGraf and TRAC, Eurofins has assembled the largest transplant
diagnostics sales force, and has the most comprehensive portfolio
of non-invasive kidney rejection tests available today, and is
focused on aggressively growing beyond blood tests for kidney with
more technologies and more organs. Combining this group expertise
and Eurofin's resources in research and development, this advisory
board is uniquely positioned to drive clinical value throughout the
transplant community.
For information on ordering tests and arranging remote sample
collection, physicians may contact TGI about TruGraf tests by
calling 1-844-TruGraf. Ordering and general information is also
available on our websites at www.trugraf.com. For information
on ordering or remote collection for TRAC or other Viracor
products, please call 800.305.5198 or email
info@viracor-eurofins.com.
About Transplant Genomics, Inc.
Transplant Genomics, Inc. ("TGI") is a personalized diagnostics
company committed to improving organ transplant outcomes worldwide
through innovative tests that detect early signs of graft injury,
differentiate among actionable causes and enable the optimization
of therapy. Working alongside the transplant community and within
the Eurofins family, TGI is commercializing a suite of tests
enabling diagnoses and prediction of transplant recipient immune
status. Our flagship product is TruGraf, the only blood test
approved by CMS for surveillance and to rule out "silent"
subclinical acute rejection in kidney transplant recipients with
stable graft function. Test services are offered through TGI's CLIA
laboratory in Fremont, CA. TGI was
acquired by Eurofins in 2019.
ABOUT VIRACOR
With over 30 years of specialized expertise in infectious
disease, immunology and allergy testing for immunocompromised and
critical patients, Viracor Eurofins is committed to helping medical
professionals, transplant teams, reference laboratories and
biopharmaceutical companies get results faster, when it matters
most. Viracor is passionate about delivering value to its clients
by providing timely, actionable information, never losing sight of
the connection between the testing it performs and the patients it
ultimately serves. Viracor is a 100 percent subsidiary of Eurofins
Scientific (EUFI.PA), the global leader in bio-analytical testing,
and one of the world leaders in genomic services. For more
information, please visit https://www.eurofins.com/ and
https://www.viracor-eurofins.com/.
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes "Eurofins" or "the Group") believes it is a scientific
leader in food, environment, pharmaceutical and cosmetics products
testing and in agroscience CRO services. It is also one of the
global independent market leaders in certain testing and laboratory
services for genomics, discovery pharmacology, forensics, CDMO,
advanced material sciences and for supporting clinical studies. In
addition, Eurofins is one of the leading global emerging players in
specialty clinical diagnostic testing. With about 45,000 staff in
more than 800 laboratories across 47 countries, Eurofins offers a
portfolio of over 200,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients' increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific's management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company's management as of the date of
publication, but no guarantee can be made as to their validity.
Media Contact
Sloane Heller Communications
sloane@sloanehellermedia.com
917.432.4194
View original content to download
multimedia:http://www.prnewswire.com/news-releases/tgi-and-viracor-announce-transplant-advisory-board-301070446.html
SOURCE Transplant Genomics, Inc.
